The Federal Trade Commission accuses CVS, Cigna and UnitedHealth of artificially inflating prices on specialty generic drugs by $7.3 billion over six years.

The Federal Trade Commission suggests that PBMs profit from specialty generic drugs such as those for cancer and HIV and ...

Pharmacy benefit managers, which serve as the middlemen between drug makers, insurers and pharmacies, reaped $7.3 billion in ...

The Federal Trade Commission (FTC) on Tuesday released its second interim report on pharmacy benefit managers (PBM), saying ...

Three major drug middlemenneedlessly marked up generic drugs for cancer, HIV, and multiple sclerosis to generate $7.3 billion ...

Caremark is a subsidiary of CVS, Express Scripts is owned by Cigna (NYSE:CI), and United Health owns OptumRx. The FTC's report reveals that these PBMs have marked up the prices of a variety of ...

Dumbo Market has flapped its ears across the East River to land at the site of a former CVS on the Upper East Side.

Explore the ongoing CVS Health stock performance and what to expect in the next few months as investors watch the ongoing ...

The pharmaceutical landscape enters 2025 with a mix of challenges and opportunities, with the potential to shape the future ...

CVS Health ( CVS 4.35%) is a stock that's been struggling badly for multiple years and is coming off a brutal performance in ...

CVS’ efforts to reform how its pharmacies are paid have reached a significant milestone that should stabilize flagging ...

Restaurants generally did not have a very good 2024. Some forecasts suggest 2025 could be just as bad, or worse. Red Lobster and TGI Fridays are just a couple of the chains that struggled last yea ...